Cargando…

Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience

AIMS: Heart failure with reduced ejection fraction (HFrEF) is associated with excessive sympathetic and impaired parasympathetic activity. The Barostim Neo™ device is used for electronical baroreflex activation therapy (BAT) to counteract autonomic nervous system dysbalance. Randomized trials have s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blanco, Carola, Madej, Tomas, Mangner, Norman, Hommel, Jennifer, Grimm, Susanna, Knaut, Michael, Linke, Axel, Winzer, Ephraim B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682889/ https://www.ncbi.nlm.nih.gov/pubmed/37667319 http://dx.doi.org/10.1002/ehf2.14508

Ejemplares similares

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction
por: Ellingsen, Øyvind, et al.
Publicado: (2017)

Muscular changes in animal models of heart failure with preserved ejection fraction: what comes closest to the patient?
por: Goto, Keita, et al.
Publicado: (2020)

Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review
por: Molina‐Linde, Juan Máximo, et al.
Publicado: (2023)

Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2017)

Updates on Baroreflex Activation Therapy and Vagus Nerve Stimulation for Treatment of Heart Failure With Reduced Ejection Fraction
por: Babar, Natasha, et al.
Publicado: (2022)

Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy
por: Nottebohm, Pia I., et al.
Publicado: (2022)

Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review
por: Schmidt, Rodrigo, et al.
Publicado: (2020)

Oscillatory Pattern of Sympathetic Nerve Bursts Is Associated With Baroreflex Function in Heart Failure Patients With Reduced Ejection Fraction
por: Toschi-Dias, Edgar, et al.
Publicado: (2021)

Peak O(2)‐pulse predicts exercise training‐induced changes in peak V̇O(2) in heart failure with preserved ejection fraction
por: Mueller, Stephan, et al.
Publicado: (2022)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
por: Adams, Volker, et al.
Publicado: (2021)

Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results
por: Piayda, Kerstin, et al.
Publicado: (2022)

Myocardial infarction with a preserved ejection fraction—the impaired function of the cardio-renal baroreflex
por: Pickny, Lisa, et al.
Publicado: (2023)

Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials
por: Coats, Andrew J.S., et al.
Publicado: (2022)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model
por: Winzer, Ephraim B., et al.
Publicado: (2022)

Physical Activity in the Prevention and Treatment of Coronary Artery Disease
por: Winzer, Ephraim Bernhard, et al.
Publicado: (2018)

Cerebral Protection Devices during Transcatheter Interventions: Indications, Benefits, and Limitations
por: Haussig, Stephan, et al.
Publicado: (2020)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: AbouEzzeddine, Omar F., et al.
Publicado: (2017)

Respiratory patterns and baroreflex function in heart failure
por: Radaelli, Alberto, et al.
Publicado: (2023)

Exercise training and high‐sensitivity cardiac troponin T in patients with heart failure with reduced ejection fraction
por: Koppen, Elias, et al.
Publicado: (2021)

Treatment of Heart Failure With Normal Ejection Fraction
por: Hamdani, Nazha, et al.
Publicado: (2010)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Heart Failure with Reduced Ejection Fraction: The Role of Cardiovascular and Lung Ultrasound beyond Ejection Fraction
por: Shahnazaryan, Syuzanna, et al.
Publicado: (2023)

Heart Failure With Preserved Ejection Fraction vs. Reduced Ejection Fraction　― Mechanisms of Ventilatory Inefficiency During Exercise in Heart Failure ―
por: Tsujinaga, Shingo, et al.
Publicado: (2020)

Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021)

Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure
por: Winzer, Ephraim B., et al.
Publicado: (2016)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature
por: Techorueangwiwat, Chol, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kicm3g53r9p6shtaftj9fuf7kd